Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
TECPETROL URGES ALPHA LITHIUM SHAREHOLDERS TO TENDER AS SOON AS POSSIBLE, FOLLOWING POSITIVE RECOMMENDATION BY THE ALPHA BOARD OF DIRECTORS AHEAD OF BID DEADLINE OF 3 OCTOBER 2023
Published: 2023-09-29 (Crawled : 12:00) - prnewswire.com
TX | News | $39.9 -0.25% 0.0% 170K
|
Non-Energy Minerals
|
| O: 0.95%
H: 1.02%
C: -1.19%
TS | News | $31.6 -1.47% 0.0% 1.6M
|
Non-Energy Minerals
|
| O: 0.0%
H: 0.38%
C: -0.91%
LTUM | News | $0.092 15.91% 85K
|
Mining, Quarrying, and Oil and ...
|
| O: 0.0%
H: 0.0%
C: -7.61%
lithium positive deadline
Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update
Published: 2023-09-29 (Crawled : 12:00) - globenewswire.com
GPCR | News | $50.42 34.56% 25.68% 10M
|
n/a
|
| O: 78.13%
H: 0.65%
C: -22.54%
gsbr-1290 agonist positive update program therapeutics results study
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy
Published: 2023-09-29 (Crawled : 12:00) - globenewswire.com
CAPR | News 0 d | $3.415 -41.27% -70.28% 2.7M
|
Health Technology
|
| O: -35.94%
H: 1.1%
C: -11.17%
cap-1002 fda positive meeting therapeutics duchenne
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
Published: 2023-09-29 (Crawled : 00:00) - prnewswire.com
MS | News 3 d | $81.67 -0.63% 0.01% 6.8M
|
Finance
|
| O: 1.83%
H: 0.0%
C: 0.0%
asc22 hepatitis cure positive expansion
Vericel Announces Publication of Positive Results from Phase 3 Debride and Protect (DETECT) Study of Thermal Burn Patients Treated with NexoBrid
Published: 2023-09-28 (Crawled : 13:00) - globenewswire.com
VCEL | $33.57 -1.53% -1.55% 400K
|
Health Technology
|
| O: 0.73%
H: 0.59%
C: -4.72%
MDWD | $10.89 0.18% 0.18% 18K
|
Health Technology
|
| O: 0.33%
H: 19.07%
C: 17.77%
nexobrid positive publication results study
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
Published: 2023-09-28 (Crawled : 12:00) - globenewswire.com
ARDX | $4.08 0.99% 0.98% 4.8M
|
Health Technology
|
| O: 0.61%
H: 0.96%
C: -2.65%
positive publication tenapanor trial results
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
Published: 2023-09-28 (Crawled : 10:00) - globenewswire.com
BNOX | $2.76 -18.1% -22.1% 6.6M
|
n/a
|
| O: 480.71%
H: 12.06%
C: -41.08%
bnc210 positive topline trial results
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
Published: 2023-09-26 (Crawled : 20:00) - globenewswire.com
ADVM | $1.49 -2.61% -2.68% 210K
|
Health Technology
|
| O: 0.0%
H: 1.74%
C: -2.91%
positive protein trial
Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
Published: 2023-09-26 (Crawled : 20:00) - prnewswire.com
CRDF | $1.385 -3.15% -3.25% 1.2M
|
Health Services
|
| O: 17.9%
H: 4.97%
C: -16.23%
lung positive onvansertib cancer pancreatic cell
BullFrog AI Announces Positive Data from Preclinical Study Evaluating Novel Prodrug of Mebendazole for Treatment of Glioblastoma
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
BFRG | $3.245 -4.84% -5.08% 120K
|
n/a
|
| O: 8.71%
H: 37.18%
C: 13.78%
positive treatment preclinical glioblastoma study
Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
ARVL | News | $1.15 0.0% 97K
|
Manufacturing
|
| O: -1.24%
H: 0.0%
C: 0.0%
PLRX | $17.35 5.79% 5.48% 890K
|
Health Technology
|
| O: 7.89%
H: 11.25%
C: 5.98%
liver positive fibrosis bexotegrast trial therapeutics
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
SLNO 1 d | $29.41 6.6% 6.19% 3M
|
Health Technology
|
| O: 371.91%
H: 44.29%
C: 27.62%
positive therapeutics results study
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
Published: 2023-09-26 (Crawled : 12:00) - globenewswire.com
INZY | $4.205 -0.47% -0.48% 600K
|
Health Technology
|
| O: -4.12%
H: 17.12%
C: 8.65%
inz-701 pharma positive ongoing trials
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
Published: 2023-09-26 (Crawled : 11:00) - prnewswire.com
IONS S | $45.35 -1.97% -2.01% 1.3M
|
Health Technology
|
| O: 3.61%
H: 5.92%
C: 5.33%
positive topline results study
Vigil Neuroscience Receives Positive Opinion from European Medicines Agency on Orphan Drug Designation for VGL101 for the Treatment of ALSP
Published: 2023-09-26 (Crawled : 11:00) - globenewswire.com
VIGL | $5.48 -6.16% -6.57% 20K
|
|
| O: -4.73%
H: 13.7%
C: 3.94%
vgl101 drug positive treatment designation
Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Published: 2023-09-26 (Crawled : 10:00) - globenewswire.com
ROIV M 3 d | $11.7 -6.77% -7.26% 17M
|
Manufacturing
|
| O: 18.36%
H: 8.73%
C: 5.17%
IMVT 3 d | $38.41 -3.47% -3.59% 2.6M
|
Health Technology
|
| O: 61.13%
H: 29.2%
C: 23.75%
imvt-1402 positive results
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
Published: 2023-09-26 (Crawled : 10:00) - globenewswire.com
IMVT 3 d | $38.41 -3.47% -3.59% 2.6M
|
Health Technology
|
| O: 61.13%
H: 29.2%
C: 23.75%
imvt-1402 positive results
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138Further Supports TTX-MC138 Application in Brain Cancer
Published: 2023-09-25 (Crawled : 17:00) - biospace.com/
RNAZ 1 d | $0.5 -13.09% -15.06% 4.8M
|
Professional, Scientific, and T...
|
| O: 94.28%
H: 0.0%
C: 0.0%
mc138 ttx-mc138 pre-clinical positive cancer application therapeutics results glioblastoma
TransCode Therapeutics Announces Positive Pre-Clinical Glioblastoma Results with Lead Therapeutic Candidate, TTX-MC138
Published: 2023-09-25 (Crawled : 13:00) - globenewswire.com
RNAZ 1 d | $0.5 -13.09% -15.06% 4.8M
|
Professional, Scientific, and T...
|
| O: 94.28%
H: 0.0%
C: 0.0%
mc138 ttx-mc138 pre-clinical positive therapeutics results glioblastoma
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
Published: 2023-09-22 (Crawled : 21:00) - globenewswire.com
MORF | $22.88 1.73% 1.7% 2.5M
|
Health Technology
| Email alert
Add to watchlist
morf-057 positive
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
LVS 4 | $45.84 0.64% 6.58% 4.6M
|
Consumer Services
MRDB 4 | $0.43 -8.49% 4.65% 230K
|
n/a
CANO | News | $0.2536 -10.07% 4.42% 3.5M
|
Health Care and Social Assistan...
TUP | $1.4 -10.83% 4.29% 2.5M
|
Producer Manufacturing
KNW 4 | $0.25 8.51% 4.0% 960K
|
Manufacturing
AULT | $0.3227 -19.38% 3.5% 3M
|
Manufacturing
RC | $10.11 -0.39% 3.16% 1.1M
|
Finance
GFI | $10.86 -0.27% 3.04% 3.8M
|
Non-Energy Minerals
VQS | $0.16 3.03% 1M
|
Information
ASXC | $0.27 -2.88% 2.85% 740K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.